patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_151610 | REC_0013901 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.8 | 72 | female | 2 | 25 | 4.8 | 2 | sotorasib 960 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:00.572891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939826 | REC_0013902 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 9.2 | 72 | male | 1 | 23 | 5.2 | 1 | entrectinib 600 mg daily | 27.8 | true | MSS | 2026-03-15T05:36:00.573196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700913 | REC_0013903 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.4 | 73 | female | 1 | 10 | 4.4 | 2 | sotorasib 960 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:36:00.573479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799755 | REC_0013904 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.1 | 76 | female | 0 | 19 | 3.9 | 6 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:36:00.573773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884311 | REC_0013905 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 10.9 | 66 | female | 1 | 25 | 7.5 | 5 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:36:00.574075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820722 | REC_0013906 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.6 | 65 | male | 0 | 29 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:36:00.574356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561926 | REC_0013907 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.8 | 68 | female | 1 | 9 | 4.7 | 6 | entrectinib 600 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:36:00.574754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580764 | REC_0013908 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 7.6 | 61 | female | 1 | 14 | 4.8 | 1 | sotorasib 960 mg daily | 16.9 | false | MSS | 2026-03-15T05:36:00.575122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843222 | REC_0013909 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13.6 | 59 | male | 0 | 14 | 4.7 | 4 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:36:00.575448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581816 | REC_0013910 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.1 | 82 | female | 2 | 6 | 3.8 | 7 | alectinib 600 mg BID | 15.1 | false | MSS | 2026-03-15T05:36:00.575748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292266 | REC_0013911 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 6.6 | 66 | female | 0 | 4 | 8.6 | 1 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:36:00.576299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241533 | REC_0013912 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 11 | 63 | female | 0 | 0 | 6.2 | 2 | alectinib 600 mg BID | 21.4 | false | MSI-H | 2026-03-15T05:36:00.576672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936370 | REC_0013913 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 5.2 | 80 | female | 2 | 68 | 5.9 | 3 | pembrolizumab 200 mg q3w | 21.1 | false | MSS | 2026-03-15T05:36:00.576970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134796 | REC_0013914 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.5 | 56 | female | 0 | 13 | 4.8 | 6 | alectinib 600 mg BID | 7.6 | true | MSI-H | 2026-03-15T05:36:00.577288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153262 | REC_0013915 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 20.7 | 75 | female | 2 | 12 | 4.4 | 8 | alectinib 600 mg BID | 10.7 | false | MSI-H | 2026-03-15T05:36:00.577620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305166 | REC_0013916 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 18 | 3.8 | 63 | female | 1 | 8 | 4.7 | 1 | pembrolizumab 200 mg q3w | 12.3 | true | MSS | 2026-03-15T05:36:00.577953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617648 | REC_0013917 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.4 | 72 | female | 1 | 14 | 4.2 | 1 | osimertinib 80 mg daily | 13.9 | true | MSS | 2026-03-15T05:36:00.578285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730125 | REC_0013918 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 5.8 | 63 | male | 0 | 15 | 5.9 | 0 | osimertinib 80 mg daily | 24.1 | true | MSS | 2026-03-15T05:36:00.578634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895046 | REC_0013919 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14.8 | 56 | female | 0 | 14 | 5.5 | 4 | alectinib 600 mg BID | 6.2 | true | MSS | 2026-03-15T05:36:00.578996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769858 | REC_0013920 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.8 | 70 | male | 2 | 13 | 6 | 2 | alectinib 600 mg BID | 18.6 | false | MSS | 2026-03-15T05:36:00.579358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586252 | REC_0013921 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 11.3 | 60 | male | 1 | 21 | 8.7 | 0 | sotorasib 960 mg daily | 37.8 | false | MSI-H | 2026-03-15T05:36:00.579710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324661 | REC_0013922 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.6 | 68 | female | 1 | 16 | 7.2 | 6 | pembrolizumab 200 mg q3w | 9.9 | true | MSS | 2026-03-15T05:36:00.580159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898250 | REC_0013923 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.9 | 66 | male | 1 | 62 | 4.6 | 2 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:36:00.580689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312622 | REC_0013924 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 8.9 | 60 | male | 0 | 27 | 8.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:36:00.581411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477667 | REC_0013925 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4 | 84 | male | 1 | 44 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:36:00.581900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552616 | REC_0013926 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.3 | 59 | male | 1 | 16 | 5.1 | 6 | alectinib 600 mg BID | 12.5 | false | MSS | 2026-03-15T05:36:00.582366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442301 | REC_0013927 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.7 | 62 | male | 0 | 11 | 6.5 | 2 | alectinib 600 mg BID | 16.2 | true | MSS | 2026-03-15T05:36:00.582765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971121 | REC_0013928 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 11.5 | 79 | female | 1 | 22 | 3.8 | 6 | entrectinib 600 mg daily | 8.1 | true | MSI-H | 2026-03-15T05:36:00.583112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903571 | REC_0013929 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.3 | 76 | female | 1 | 31 | 5.7 | 8 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:00.583441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720722 | REC_0013930 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8 | 54 | female | 0 | 17 | 3.7 | 4 | entrectinib 600 mg daily | 8.8 | true | MSS | 2026-03-15T05:36:00.583791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604808 | REC_0013931 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.7 | 62 | male | 0 | 14 | 5.6 | 6 | entrectinib 600 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:00.584212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764173 | REC_0013932 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 17 | 68 | female | 1 | 19 | 6.4 | 5 | sotorasib 960 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:36:00.584558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462395 | REC_0013933 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 18.9 | 68 | female | 0 | 7 | 5 | 6 | osimertinib 80 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:36:00.584884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293755 | REC_0013934 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 13.2 | 63 | male | 1 | 7 | 5.2 | 5 | pembrolizumab 200 mg q3w | 16.7 | false | MSS | 2026-03-15T05:36:00.585221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713164 | REC_0013935 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 11.9 | 73 | female | 2 | 21 | 5.2 | 2 | entrectinib 600 mg daily | 41.8 | false | MSS | 2026-03-15T05:36:00.585596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422161 | REC_0013936 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 7.9 | 69 | female | 1 | 56 | 6.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 41.7 | false | MSS | 2026-03-15T05:36:00.585986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216268 | REC_0013937 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 5.2 | 61 | female | 0 | 12 | 5.8 | 2 | osimertinib 80 mg daily | 24.1 | false | MSS | 2026-03-15T05:36:00.586517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728668 | REC_0013938 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 16.6 | 77 | female | 2 | 9 | 6.3 | 1 | pembrolizumab 200 mg q3w | 22.9 | false | MSS | 2026-03-15T05:36:00.586917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913682 | REC_0013939 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.3 | 79 | female | 1 | 20 | 6.2 | 4 | osimertinib 80 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:36:00.587294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542913 | REC_0013940 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.5 | 69 | female | 1 | 39 | 4.9 | 2 | pembrolizumab 200 mg q3w | 16.1 | true | MSS | 2026-03-15T05:36:00.587792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165644 | REC_0013941 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.4 | 51 | female | 0 | 12 | 4.8 | 3 | pembrolizumab 200 mg q3w | 7.9 | false | MSS | 2026-03-15T05:36:00.588296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929026 | REC_0013942 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 18.2 | 66 | female | 1 | 17 | 6 | 3 | pembrolizumab 200 mg q3w | 9.3 | true | MSS | 2026-03-15T05:36:00.588705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173796 | REC_0013943 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 13 | 7.8 | 73 | female | 1 | 17 | 7.9 | 1 | pembrolizumab 200 mg q3w | 27.9 | true | MSS | 2026-03-15T05:36:00.589054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704820 | REC_0013944 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 13 | 76 | female | 1 | 16 | 4 | 2 | sotorasib 960 mg daily | 21.9 | true | MSI-H | 2026-03-15T05:36:00.589383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458714 | REC_0013945 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.6 | 76 | female | 2 | 16 | 4.9 | 2 | sotorasib 960 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:36:00.589695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891030 | REC_0013946 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 11.4 | 63 | female | 1 | 12 | 6.3 | 1 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:36:00.589994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862221 | REC_0013947 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.5 | 56 | female | 0 | 20 | 4.7 | 6 | osimertinib 80 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:36:00.590294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718501 | REC_0013948 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.9 | 71 | female | 1 | 16 | 5 | 5 | alectinib 600 mg BID | 15.3 | false | MSI-H | 2026-03-15T05:36:00.590584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171671 | REC_0013949 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 6.1 | 84 | female | 2 | 33 | 5.4 | 4 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:36:00.590875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689878 | REC_0013950 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 19.6 | 80 | female | 2 | 15 | 4.5 | 4 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:36:00.591361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388106 | REC_0013951 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.6 | 79 | female | 1 | 23 | 6.7 | 2 | osimertinib 80 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:36:00.591852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655710 | REC_0013952 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10.8 | 60 | male | 0 | 14 | 4.2 | 2 | osimertinib 80 mg daily | 15.4 | true | MSS | 2026-03-15T05:36:00.592399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428520 | REC_0013953 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 8.3 | 83 | female | 1 | 9 | 6.6 | 7 | alectinib 600 mg BID | 14.4 | false | MSS | 2026-03-15T05:36:00.592793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468773 | REC_0013954 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.7 | 75 | female | 1 | 13 | 5.3 | 2 | sotorasib 960 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:36:00.593155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366914 | REC_0013955 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.9 | 51 | male | 0 | 10 | 5.1 | 8 | entrectinib 600 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:00.593589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607135 | REC_0013956 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 5.5 | 58 | male | 1 | 9 | 4 | 4 | alectinib 600 mg BID | 11.8 | true | MSS | 2026-03-15T05:36:00.593983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168584 | REC_0013957 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 6 | 50 | male | 0 | 83 | 5.1 | 5 | pembrolizumab 200 mg q3w | 5.5 | false | MSS | 2026-03-15T05:36:00.594360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520828 | REC_0013958 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 8.3 | 70 | female | 2 | 100 | 7.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.6 | false | MSS | 2026-03-15T05:36:00.594717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666327 | REC_0013959 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.3 | 70 | female | 2 | 50 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.8 | false | MSS | 2026-03-15T05:36:00.595061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484141 | REC_0013960 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 10.6 | 70 | male | 2 | 20 | 4.6 | 1 | pembrolizumab 200 mg q3w | 14.9 | true | MSI-H | 2026-03-15T05:36:00.595414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191341 | REC_0013961 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 2.8 | 78 | female | 2 | 46 | 6 | 5 | pembrolizumab 200 mg q3w | 6.8 | true | MSS | 2026-03-15T05:36:00.595768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612806 | REC_0013962 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.9 | 64 | male | 0 | 7 | 5.5 | 5 | alectinib 600 mg BID | 14.7 | false | MSS | 2026-03-15T05:36:00.596186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482414 | REC_0013963 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.4 | 80 | female | 2 | 20 | 6.2 | 1 | pembrolizumab 200 mg q3w | 27.8 | true | MSS | 2026-03-15T05:36:00.596699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925239 | REC_0013964 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 7.2 | 67 | female | 0 | 3 | 4.6 | 1 | pembrolizumab 200 mg q3w | 29.7 | false | MSS | 2026-03-15T05:36:00.597231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168724 | REC_0013965 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11 | 82 | female | 2 | 13 | 5.8 | 1 | alectinib 600 mg BID | 14.2 | true | MSI-H | 2026-03-15T05:36:00.597684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105021 | REC_0013966 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.8 | 44 | female | 0 | 26 | 7.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:36:00.598075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878634 | REC_0013967 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7 | 64 | male | 1 | 15 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.8 | true | MSS | 2026-03-15T05:36:00.598483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225801 | REC_0013968 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 10.6 | 65 | female | 1 | 23 | 7.4 | 1 | sotorasib 960 mg daily | 18.9 | false | MSI-H | 2026-03-15T05:36:00.598865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420819 | REC_0013969 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 16 | 16.1 | 65 | male | 1 | 11 | 5.2 | 2 | pembrolizumab 200 mg q3w | 20.5 | true | MSS | 2026-03-15T05:36:00.599229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376911 | REC_0013970 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8 | 72 | male | 2 | 11 | 6.2 | 4 | alectinib 600 mg BID | 12.5 | true | MSS | 2026-03-15T05:36:00.599615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114199 | REC_0013971 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 9 | 65 | female | 2 | 6 | 5.2 | 2 | entrectinib 600 mg daily | 6.3 | false | MSS | 2026-03-15T05:36:00.600008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963825 | REC_0013972 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13.2 | 71 | female | 1 | 14 | 4.8 | 2 | alectinib 600 mg BID | 21.4 | true | MSS | 2026-03-15T05:36:00.600612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511311 | REC_0013973 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15 | 65 | female | 1 | 12 | 6.8 | 7 | osimertinib 80 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:36:00.601064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153562 | REC_0013974 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 17 | 57 | female | 1 | 2 | 7.1 | 6 | sotorasib 960 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:36:00.601507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899333 | REC_0013975 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 12.5 | 68 | female | 1 | 10 | 4.9 | 0 | osimertinib 80 mg daily | 20.6 | false | MSS | 2026-03-15T05:36:00.601933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161325 | REC_0013976 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12.3 | 81 | female | 2 | 19 | 6.1 | 8 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:36:00.602494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988089 | REC_0013977 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 21 | 7.2 | 69 | female | 0 | 31 | 6.2 | 0 | pembrolizumab 200 mg q3w | 23.7 | true | MSS | 2026-03-15T05:36:00.602890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450893 | REC_0013978 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 34 | 7.1 | 68 | female | 1 | 21 | 5 | 3 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:36:00.603344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907034 | REC_0013979 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 11.4 | 74 | female | 1 | 12 | 4.6 | 4 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:00.603761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290244 | REC_0013980 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.8 | 80 | female | 1 | 16 | 4.1 | 5 | sotorasib 960 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:36:00.604214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205139 | REC_0013981 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.7 | 80 | female | 2 | 25 | 5.6 | 5 | sotorasib 960 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:00.604643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853853 | REC_0013982 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 18.5 | 76 | female | 2 | 11 | 4.6 | 3 | alectinib 600 mg BID | 7.9 | false | MSI-H | 2026-03-15T05:36:00.605031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535440 | REC_0013983 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 22.2 | 77 | male | 1 | 19 | 4.1 | 1 | alectinib 600 mg BID | 15 | false | MSS | 2026-03-15T05:36:00.605389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350477 | REC_0013984 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 15.4 | 69 | female | 0 | 6 | 4.8 | 7 | entrectinib 600 mg daily | 9.7 | true | MSS | 2026-03-15T05:36:00.605727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742839 | REC_0013985 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 8.8 | 67 | female | 1 | 22 | 5 | 2 | pembrolizumab 200 mg q3w | 19.5 | false | MSS | 2026-03-15T05:36:00.606067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356699 | REC_0013986 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.4 | 67 | female | 1 | 7 | 6.2 | 2 | pembrolizumab 200 mg q3w | 18.7 | false | MSS | 2026-03-15T05:36:00.606419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392495 | REC_0013987 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.5 | 46 | male | 0 | 9 | 3.1 | 7 | osimertinib 80 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:00.606752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723562 | REC_0013988 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.4 | 68 | female | 1 | 13 | 5.4 | 5 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:36:00.607059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774867 | REC_0013989 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 13.3 | 68 | male | 0 | 11 | 4.6 | 2 | osimertinib 80 mg daily | 21.6 | false | MSS | 2026-03-15T05:36:00.607553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505587 | REC_0013990 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6 | 58 | female | 1 | 27 | 9 | 3 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:36:00.607918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520244 | REC_0013991 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 11.8 | 51 | male | 0 | 7 | 3.7 | 5 | osimertinib 80 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:36:00.608325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669255 | REC_0013992 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 11.8 | 47 | male | 0 | 11 | 5.1 | 1 | osimertinib 80 mg daily | 20.3 | true | MSI-H | 2026-03-15T05:36:00.608671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781349 | REC_0013993 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 10 | 68 | female | 0 | 16 | 5.1 | 3 | sotorasib 960 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:36:00.609022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829796 | REC_0013994 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.8 | 74 | female | 3 | 12 | 5.2 | 6 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:36:00.609361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165154 | REC_0013995 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 4.8 | 51 | male | 0 | 15 | 5.3 | 7 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.609691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458582 | REC_0013996 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12 | 64 | male | 1 | 22 | 6.4 | 8 | osimertinib 80 mg daily | 18 | false | MSI-H | 2026-03-15T05:36:00.610046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393187 | REC_0013997 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.9 | 65 | female | 1 | 17 | 4.4 | 4 | osimertinib 80 mg daily | 4.7 | true | MSS | 2026-03-15T05:36:00.610393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988278 | REC_0013998 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.1 | 77 | female | 1 | 23 | 6.8 | 5 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:36:00.610745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496872 | REC_0013999 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 1.6 | 70 | female | 2 | 81 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:36:00.611092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167449 | REC_0014000 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.1 | 65 | male | 1 | 19 | 5.1 | 2 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:00.611417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.